Cellectar Biosciences (CLRB) CEO awarded 250,000 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cellectar Biosciences President & CEO James V. Caruso received a grant of stock options to acquire 250,000 shares of common stock at an exercise price of $3.14 per share. These options were contingently granted on May 28, 2026, subject to stockholder approval of the amended 2021 Stock Incentive Plan.
Stockholders approved the amended plan at Cellectar’s 2026 Annual Meeting of Stockholders on July 7, 2026, activating the grant. The options expire on May 28, 2036 and vest over three years, with one-third vesting on May 28, 2027 and the remainder vesting in 24 equal monthly installments thereafter.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
CARUSO JAMES V
Role
President & CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 250,000 | $0.00 | -- |
Holdings After Transaction:
Stock option (right to buy) — 250,000 shares (Direct, null)
Footnotes (1)
- This option was contingently granted on May 28, 2026, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2026 Annual Meeting of Stockholders. Such stockholder approval was obtained on July 7, 2026. This option shall vest over a period of three years from May 28, 2026, with 1/3 vesting on the first anniversary of May 28, 2026, and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of May 28, 2026
Key Figures
Option grant size: 250,000 options
Exercise price: $3.14 per share
Total derivatives after grant: 250,000 options
+3 more
6 metrics
Option grant size
250,000 options
Stock option grant to CEO for common stock
Exercise price
$3.14 per share
Exercise price of CEO stock options
Total derivatives after grant
250,000 options
Total options held following this transaction
Option expiration date
May 28, 2036
Expiration of the CEO stock options
Vesting start
May 28, 2027
One-third of options vest on first anniversary
Remaining vesting period
24 monthly installments
Two-thirds vest over 24 months after first anniversary
Key Terms
Stock option (right to buy), exercise price, vesting, 2021 Stock Incentive Plan, +1 more
5 terms
Stock option (right to buy) financial
"security_title: Stock option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 3.1400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"This option shall vest over a period of three years"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
2021 Stock Incentive Plan financial
"approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan"
Annual Meeting of Stockholders financial
"at Cellectar's 2026 Annual Meeting of Stockholders"
FAQ
What insider transaction did Cellectar Biosciences (CLRB) report in this Form 4?
Cellectar Biosciences reported a compensation-related stock option grant to President & CEO James V. Caruso for 250,000 shares of common stock at a $3.14 exercise price. This is an options award, not an open-market stock purchase or sale.
How many Cellectar (CLRB) stock options were granted to the CEO and at what exercise price?
The CEO received stock options covering 250,000 shares of Cellectar common stock with an exercise price of $3.14 per share. The award represents a right to buy shares in the future rather than an immediate purchase of common stock in the market.
What is the vesting schedule for the new Cellectar (CLRB) CEO stock options?
The options vest over three years from May 28, 2026. One-third vests on the first anniversary, May 28, 2027, and the remaining two-thirds vest in 24 equal monthly installments beginning on that first anniversary, creating a gradual vesting profile tied to continued service.
When do the Cellectar (CLRB) CEO stock options expire and what is the term?
The stock options expire on May 28, 2036, giving a ten-year term from the contingent grant date of May 28, 2026. This long-dated expiration allows extended time for potential exercise, consistent with typical senior executive equity incentive structures.
Does this Cellectar (CLRB) Form 4 indicate any open-market buying or selling by the CEO?
No. The Form 4 reflects a grant of stock options coded as a grant, award, or other acquisition, not an open-market purchase or sale of common stock. It represents equity-based compensation, giving the CEO a future right to buy shares at $3.14 per share.